Budesonide as maintenance treatment in Crohn's disease: A placebo-controlled trial

S. Hanauer*, W. J. Sandborn, A. Persson, T. Persson

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

70 Scopus citations


Aim: To assess the efficacy and safety of budesonide capsules 6 mg daily for prolongation of time to relapse and maintenance of remission in patients with Crohn's disease (CD) affecting the ileum and/or ascending colon. Methods: In a double-blind, placebo-controlled, multicentre trial, 110 patients with CD, who had previously achieved remission in a placebo-controlled trial of budesonide 9 mg daily, were randomly assigned to receive budesonide 6 mg once daily or placebo for 52 weeks. Primary outcome measure was time to relapse [CD activity index (CDAI) of >150 plus an increase of at least 60 points from study entry or withdrawal due to clinical deterioration]. Results: Median time to relapse was 360 days for budesonide patients; 169 days for placebo patients (P = 0.132). No significant differences were seen between groups in relapse rates at 1 year. Budesonide was safe and well tolerated, with a similar adverse events profile to placebo. Conclusion: Patients treated with budesonide 6 mg once daily had a trend towards a prolonged time to relapse and lower CDAI scores compared with patients treated with placebo, but relapse rates were not significantly different at the 1-year end point.

Original languageEnglish (US)
Pages (from-to)363-371
Number of pages9
JournalAlimentary Pharmacology and Therapeutics
Issue number4
StatePublished - Feb 15 2005

ASJC Scopus subject areas

  • Gastroenterology
  • Pharmacology (medical)
  • Hepatology


Dive into the research topics of 'Budesonide as maintenance treatment in Crohn's disease: A placebo-controlled trial'. Together they form a unique fingerprint.

Cite this